Operating entity: AI Coaching Inc. d/b/a Gala GLP-1 (Delaware). A telehealth platform, not a pharmacy - clinicians are OpenLoop-affiliated medical groups, and medication is fulfilled through an undisclosed nationwide partner-pharmacy network (no specific compounder named). Compounded GLP-1/GIP is not FDA-approved.
The FDA resolved the semaglutide shortage on April 22, 2025. Compounding is permitted only for individually identified patients when a prescribing practitioner determines that the compounded preparation produces a significant difference for their patient compared to the FDA-approved product.